Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback